Cambridge, UK – 10 September 2024– Biofidelity, a leader in innovative genomic solutions, is proud to announce the establishment of a manufacturing facility dedicated to genomic assay production in the UK.
The new facility represents a commitment to advancing the UK's position at the forefront of genomic research and biotechnology, where unmet need remains for simplified genomic analysis to guide decisions in cancer research and care. It will be used to produce the company’s ASPYRE products as well as serving as a hub for manufacturing innovation, allowing Biofidelity to produce cutting-edge genomic assays for global distribution and contribute to the growth of the local biotech sector.
Located in Cambridge, one of the UK's most dynamic and innovative ecosystems, the manufacturing facility will benefit from strong industry partnerships, academic collaborations and proximity to key research institutions. The facility will focus on recruiting and training local talent, offering opportunities for the next generation of scientists and technicians in the UK.
“Biofidelity is proud to make reagents here in the UK that will enable simplified, localized biomarker testing solutions and rapid input into research projects for customers around the globe,” said Simon Knight, Executive Director of Operations, Biofidelity. “This manufacturing investment aligns with our commitment to building a sustainable and skilled workforce that will drive the future of genomic research.”
About Biofidelity’s ASPYRE® products
ASPYRE-Lung is a novel assay that dramatically simplifies and accelerates the detection of biomarkers for non-small cell lung cancer (NSCLC).
ASPYRE-Lung Research Use Only (RUO) reagents enable fast analysis of comprehensive panels of genomic biomarkers on existing PCR instruments available in laboratories around the world, without the need to send samples to a centralized lab, which often takes weeks to obtain results. ASPYRE’s high sensitivity enables testing from tissue samples with as little as 10% tumour content, compared to 20% or 30% for most competing assays.
About Biofidelity
Biofidelity is a rapidly growing commercial-stage genomic technology company dedicated to improving and extending the lives of patients with cancer by enabling better targeting of therapies, early detection of treatment resistance and routine monitoring of treatment response. Visit biofidelity.com and connect with us on LinkedIn and X.
Contact
Andrea Conners